3el7 › Citations

Small molecule recognition of c-Src via the Imatinib-binding conformation.

Dar AC, Lopez MS, Shokat KM
Chem Biol 15 1015-22 (2008)
Cited: 60 times
EuropePMC logo PMID: 18940662

Abstract

The cancer drug, Imatinib, is a selective Abl kinase inhibitor that does not inhibit the closely related kinase c-Src. This one drug and its ability to selectively inhibit Abl over c-Src has been a guiding principle in virtually all kinase drug discovery efforts in the last 15 years. A prominent hypothesis explaining the selectivity of Imatinib is that Abl has an intrinsic ability to adopt an inactive conformation (termed DFG-out), whereas c-Src appears to pay a high intrinsic energetic penalty for adopting this conformation, effectively excluding Imatinib from its ATP pocket. This explanation of the difference in binding affinity of Imatinib for Abl versus c-Src makes the striking prediction that it would not be possible to design an inhibitor that binds to the DFG-out conformation of c-Src with high affinity. We report the discovery of a series of such inhibitors. We use structure-activity relationships and X-ray crystallography to confirm our findings. These studies suggest that small molecules are capable of inducing the generally unfavorable DFG-out conformation in c-Src. Structural comparison between c-Src in complex with these inhibitors allows us to speculate on the differential selectivity of Imatinib for c-Src and Abl.

Reviews - 3el7 mentioned but not cited (2)

  1. Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors. Jha V, Macchia M, Tuccinardi T, Poli G. Cancers (Basel) 12 E2327 (2020)
  2. 4-Aminopyrazolopyrimidine scaffold and its deformation in the design of tyrosine and serine/threonine kinase inhibitors in medicinal chemistry. Chen X, Huang Y, Xu W, Cai Y, Yang Y. RSC Med Chem 13 1008-1028 (2022)

Articles - 3el7 mentioned but not cited (3)

  1. Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Garske AL, Peters U, Cortesi AT, Perez JL, Shokat KM. Proc Natl Acad Sci U S A 108 15046-15052 (2011)
  2. [Diosmetin regulates intestinal immune balance by inhibiting PI3K/AKT signaling to relieve 2, 4, 6-trinitrobenzene sulfonic acid-induced Crohn's disease-like colitis in mice]. Yang Z, Zhao T, Cheng Y, Zhou Y, Li Y, Wang X, Zhang X, Zuo L, Ge S. Nan Fang Yi Ke Da Xue Xue Bao 43 474-482 (2023)
  3. [Pachymic acid protects against Crohn's disease-like intestinal barrier injury and colitis in miceby suppressingintestinal epithelial cell apoptosis via inhibiting PI3K/AKT signaling]. Shao R, Yang Z, Zhang W, Zhang N, Zhao Y, Zhang X, Zuo L, Ge S. Nan Fang Yi Ke Da Xue Xue Bao 43 935-942 (2023)


Reviews citing this publication (8)

  1. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Dar AC, Shokat KM. Annu Rev Biochem 80 769-795 (2011)
  2. The Src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases. Shah NH, Amacher JF, Nocka LM, Kuriyan J. Crit Rev Biochem Mol Biol 53 535-563 (2018)
  3. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Eck MJ, Manley PW. Curr Opin Cell Biol 21 288-295 (2009)
  4. Designing selective inhibitors for calcium-dependent protein kinases in apicomplexans. Hui R, El Bakkouri M, Sibley LD. Trends Pharmacol Sci 36 452-460 (2015)
  5. Structural biology contributions to tyrosine kinase drug discovery. Cowan-Jacob SW, Möbitz H, Fabbro D. Curr Opin Cell Biol 21 280-287 (2009)
  6. A Drosophila approach to thyroid cancer therapeutics. Das TK, Cagan RL. Drug Discov Today Technol 10 e65-71 (2013)
  7. Understanding molecular mechanisms in cell signaling through natural and artificial sequence variation. Shah NH, Kuriyan J. Nat Struct Mol Biol 26 25-34 (2019)
  8. Allosteric networks governing regulation and catalysis of Src-family protein tyrosine kinases: implications for disease-associated kinases. Cheng HC, Johnson TM, Mills RD, Chong YP, Chan KC, Culvenor JG. Clin Exp Pharmacol Physiol 37 93-101 (2010)

Articles citing this publication (47)

  1. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Dar AC, Das TK, Shokat KM, Cagan RL. Nature 486 80-84 (2012)
  2. Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors. Wang L, Perera BG, Hari SB, Bhhatarai B, Backes BJ, Seeliger MA, Schürer SC, Oakes SA, Papa FR, Maly DJ. Nat Chem Biol 8 982-989 (2012)
  3. Structural basis for cytosolic double-stranded RNA surveillance by human oligoadenylate synthetase 1. Donovan J, Dufner M, Korennykh A. Proc Natl Acad Sci U S A 110 1652-1657 (2013)
  4. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase. Lin YL, Meng Y, Jiang W, Roux B. Proc Natl Acad Sci U S A 110 1664-1669 (2013)
  5. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors. Vijayan RS, He P, Modi V, Duong-Ly KC, Ma H, Peterson JR, Dunbrack RL, Levy RM. J Med Chem 58 466-479 (2015)
  6. Energetic dissection of Gleevec's selectivity toward human tyrosine kinases. Agafonov RV, Wilson C, Otten R, Buosi V, Kern D. Nat Struct Mol Biol 21 848-853 (2014)
  7. A new screening assay for allosteric inhibitors of cSrc. Simard JR, Klüter S, Grütter C, Getlik M, Rabiller M, Rode HB, Rauh D. Nat Chem Biol 5 394-396 (2009)
  8. Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. Yosaatmadja Y, Silva S, Dickson JM, Patterson AV, Smaill JB, Flanagan JU, McKeage MJ, Squire CJ. J Struct Biol 192 539-544 (2015)
  9. Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design. Dodson CA, Kosmopoulou M, Richards MW, Atrash B, Bavetsias V, Blagg J, Bayliss R. Biochem J 427 19-28 (2010)
  10. Active site profiling reveals coupling between domains in SRC-family kinases. Krishnamurty R, Brigham JL, Leonard SE, Ranjitkar P, Larson ET, Dale EJ, Merritt EA, Maly DJ. Nat Chem Biol 9 43-50 (2013)
  11. Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. Albaugh P, Fan Y, Mi Y, Sun F, Adrian F, Li N, Jia Y, Sarkisova Y, Kreusch A, Hood T, Lu M, Liu G, Huang S, Liu Z, Loren J, Tuntland T, Karanewsky DS, Seidel HM, Molteni V. ACS Med Chem Lett 3 140-145 (2012)
  12. Computational study of the "DFG-flip" conformational transition in c-Abl and c-Src tyrosine kinases. Meng Y, Lin YL, Roux B. J Phys Chem B 119 1443-1456 (2015)
  13. TSLP signaling network revealed by SILAC-based phosphoproteomics. Zhong J, Kim MS, Chaerkady R, Wu X, Huang TC, Getnet D, Mitchell CJ, Palapetta SM, Sharma J, O'Meally RN, Cole RN, Yoda A, Moritz A, Loriaux MM, Rush J, Weinstock DM, Tyner JW, Pandey A. Mol Cell Proteomics 11 M112.017764 (2012)
  14. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. Nagashima K, Shumway SD, Sathyanarayanan S, Chen AH, Dolinski B, Xu Y, Keilhack H, Nguyen T, Wiznerowicz M, Li L, Lutterbach BA, Chi A, Paweletz C, Allison T, Yan Y, Munshi SK, Klippel A, Kraus M, Bobkova EV, Deshmukh S, Xu Z, Mueller U, Szewczak AA, Pan BS, Richon V, Pollock R, Blume-Jensen P, Northrup A, Andersen JN. J Biol Chem 286 6433-6448 (2011)
  15. Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy. Sohl CD, Ryan MR, Luo B, Frey KM, Anderson KS. ACS Chem Biol 10 1319-1329 (2015)
  16. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases. Lin YL, Roux B. J Am Chem Soc 135 14741-14753 (2013)
  17. Endoplasmic reticulum stress-independent activation of unfolded protein response kinases by a small molecule ATP-mimic. Mendez AS, Alfaro J, Morales-Soto MA, Dar AC, McCullagh E, Gotthardt K, Li H, Acosta-Alvear D, Sidrauski C, Korennykh AV, Bernales S, Shokat KM, Walter P. Elife 4 (2015)
  18. Computational study of Gleevec and G6G reveals molecular determinants of kinase inhibitor selectivity. Lin YL, Meng Y, Huang L, Roux B. J Am Chem Soc 136 14753-14762 (2014)
  19. Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity. Kwarcinski FE, Brandvold KR, Phadke S, Beleh OM, Johnson TK, Meagher JL, Seeliger MA, Stuckey JA, Soellner MB. ACS Chem Biol 11 1296-1304 (2016)
  20. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Plenker D, Riedel M, Brägelmann J, Dammert MA, Chauhan R, Knowles PP, Lorenz C, Keul M, Bührmann M, Pagel O, Tischler V, Scheel AH, Schütte D, Song Y, Stark J, Mrugalla F, Alber Y, Richters A, Engel J, Leenders F, Heuckmann JM, Wolf J, Diebold J, Pall G, Peifer M, Aerts M, Gevaert K, Zahedi RP, Buettner R, Shokat KM, McDonald NQ, Kast SM, Gautschi O, Thomas RK, Sos ML. Sci Transl Med 9 eaah6144 (2017)
  21. A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. Choi HG, Ren P, Adrian F, Sun F, Lee HS, Wang X, Ding Q, Zhang G, Xie Y, Zhang J, Liu Y, Tuntland T, Warmuth M, Manley PW, Mestan J, Gray NS, Sim T. J Med Chem 53 5439-5448 (2010)
  22. Affinity-based probes based on type II kinase inhibitors. Ranjitkar P, Perera BG, Swaney DL, Hari SB, Larson ET, Krishnamurty R, Merritt EA, Villén J, Maly DJ. J Am Chem Soc 134 19017-19025 (2012)
  23. Affinity reagents that target a specific inactive form of protein kinases. Ranjitkar P, Brock AM, Maly DJ. Chem Biol 17 195-206 (2010)
  24. Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. Fraser C, Dawson JC, Dowling R, Houston DR, Weiss JT, Munro AF, Muir M, Harrington L, Webster SP, Frame MC, Brunton VG, Patton EE, Carragher NO, Unciti-Broceta A. J Med Chem 59 4697-4710 (2016)
  25. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors. Ung PM, Schlessinger A. ACS Chem Biol 10 269-278 (2015)
  26. Synthesis of 3-(1,2,3-triazol-1-yl)- and 3-(1,2,3-triazol-4-yl)-substituted pyrazolo[3,4-d]pyrimidin-4-amines via click chemistry: potential inhibitors of the Plasmodium falciparum PfPK7 protein kinase. Klein M, Dinér P, Dorin-Semblat D, Doerig C, Grøtli M. Org Biomol Chem 7 3421-3429 (2009)
  27. Dynamic Equilibrium of the Aurora A Kinase Activation Loop Revealed by Single-Molecule Spectroscopy. Gilburt JAH, Sarkar H, Sheldrake P, Blagg J, Ying L, Dodson CA. Angew Chem Int Ed Engl 56 11409-11414 (2017)
  28. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src. Hari SB, Perera BG, Ranjitkar P, Seeliger MA, Maly DJ. ACS Chem Biol 8 2734-2743 (2013)
  29. Dynamics of human protein kinase Aurora A linked to drug selectivity. Pitsawong W, Buosi V, Otten R, Agafonov RV, Zorba A, Kern N, Kutter S, Kern G, Pádua RA, Meniche X, Kern D. Elife 7 e36656 (2018)
  30. Scaffold mining of kinase hinge binders in crystal structure database. Xing L, Rai B, Lunney EA. J Comput Aided Mol Des 28 13-23 (2014)
  31. Assessing protein loop flexibility by hierarchical Monte Carlo sampling. Nilmeier J, Hua L, Coutsias EA, Jacobson MP. J Chem Theory Comput 7 1564-1574 (2011)
  32. Substrate activity screening with kinases: discovery of small-molecule substrate-competitive c-Src inhibitors. Breen ME, Steffey ME, Lachacz EJ, Kwarcinski FE, Fox CC, Soellner MB. Angew Chem Int Ed Engl 53 7010-7013 (2014)
  33. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template. Zhou T, Commodore L, Huang WS, Wang Y, Sawyer TK, Shakespeare WC, Clackson T, Zhu X, Dalgarno DC. Chem Biol Drug Des 75 18-28 (2010)
  34. A hexylchloride-based catch-and-release system for chemical proteomic applications. Brigham JL, Perera BG, Maly DJ. ACS Chem Biol 8 691-699 (2013)
  35. Design, Synthesis, and Characterization of a Photoactivatable Caged Prodrug of Imatinib. Zindler M, Pinchuk B, Renn C, Horbert R, Döbber A, Peifer C. ChemMedChem 10 1335-1338 (2015)
  36. The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition. Yosaatmadja Y, Patterson AV, Smaill JB, Squire CJ. Acta Crystallogr D Biol Crystallogr 71 525-533 (2015)
  37. How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture. Fang L, Vilas-Boas J, Chakraborty S, Potter ZE, Register AC, Seeliger MA, Maly DJ. ACS Chem Biol 15 2005-2016 (2020)
  38. Diversity of Long-Lived Intermediates along the Binding Pathway of Imatinib to Abl Kinase Revealed by MD Simulations. Paul F, Thomas T, Roux B. J Chem Theory Comput 16 7852-7865 (2020)
  39. Structure of the Human Protein Kinase ZAK in Complex with Vemurafenib. Mathea S, Abdul Azeez KR, Salah E, Tallant C, Wolfreys F, Konietzny R, Fischer R, Lou HJ, Brennan PE, Schnapp G, Pautsch A, Kessler BM, Turk BE, Knapp S. ACS Chem Biol 11 1595-1602 (2016)
  40. Comparing pharmacophore models derived from crystal structures and from molecular dynamics simulations. Wieder M, Perricone U, Seidel T, Boresch S, Langer T. Monatsh Chem 147 553-563 (2016)
  41. SRC kinase regulation in progressively invasive cancer. Xu W, Allbritton N, Lawrence DS. PLoS One 7 e48867 (2012)
  42. Evolution and intelligent design in drug development. Agafonov RV, Wilson C, Kern D. Front Mol Biosci 2 27 (2015)
  43. Pharmacophore-based virtual screening for the identification of the novel Src inhibitor SJG-136 against lung cancer cell growth and motility. Weng CW, Li JH, Tsai JY, Lin SH, Chang GC, Liu CC, Chen JJ. Am J Cancer Res 10 1668-1690 (2020)
  44. Type II Binders Targeting the "GLR-Out" Conformation of the Pseudokinase STRADα. Smith RHB, Khan ZM, Ung PM, Scopton AP, Silber L, Mack SM, Real AM, Schlessinger A, Dar AC. Biochemistry 60 289-302 (2021)
  45. Chemical genetic inhibition of DEAD-box proteins using covalent complementarity. Barkovich KJ, Moore MK, Hu Q, Shokat KM. Nucleic Acids Res 46 8689-8699 (2018)
  46. Effect of the SH3-SH2 domain linker sequence on the structure of Hck kinase. Meiselbach H, Sticht H. J Mol Model 17 1927-1934 (2011)
  47. TYROSINE KINASES: COMPLEX MOLECULAR SYSTEMS CHALLENGING COMPUTATIONAL METHODOLOGIES. Thomas T, Roux B. Eur Phys J B 94 203 (2021)


Quick links